Montgomery Blake K, Alimchandani Meghna, Mehta Gautam U, Dewan Ramita, Nesvick Cody L, Miettinen Markku, Heiss John D, Asthagiri Ashok R, Quezado Martha, Germanwala Anand V
Clin Neuropathol. 2016 Mar-Apr;35(2):78-83. doi: 10.5414/NP300895.
Although schwannoma and neurofibroma tumors are generally reported as distinct pathologic diagnoses, sporadic schwannoma/neurofibroma hybrid nerve sheath tumors have been reported in the general population with components of both entities. We report the clinicopathological features of these hybrid nerve sheath tumors in patients with neurofibromatosis type 2 (NF2). A retrospective review of nerve sheath tumor surgical specimens from patients with NF2 enrolled at the National Institutes of Health was performed. Those specimens reported to have schwannoma-like and neurofibromalike features were selected for further characterization by morphology, immunohistochemical panel (CD34, S100, neurofilament triplet protein (immunostain) (NFTP), epithelial membrane antigen (EMA)), and confirmation as hybrid tumors. Of 43 total NF2 patients undergoing resection of nerve sheath tumors, 11 specimens from 11 (26%) patients were found to be benign nerve sheath tumors exhibiting hybrid features of both neurofibroma and schwannoma. Immunohistochemical studies showed the schwannoma component to be S100+, CD 34- while the neurofibroma component was CD34+, variable S100+. Our experience emphasizes the importance of including this distinct tumor subtype, the schwannoma/neurofibroma hybrid tumor, in the differential diagnosis of nerve sheath tumors in NF2 patients and suggests that the relationship between neurofibroma and schwannoma tumors is closer than previously suspected..
尽管通常认为神经鞘瘤和神经纤维瘤是不同的病理诊断,但在普通人群中已报告有散发性神经鞘瘤/神经纤维瘤混合性神经鞘膜肿瘤,其具有这两种实体的成分。我们报告了2型神经纤维瘤病(NF2)患者中这些混合性神经鞘膜肿瘤的临床病理特征。对美国国立卫生研究院登记的NF2患者的神经鞘膜肿瘤手术标本进行了回顾性研究。选择那些报告具有神经鞘瘤样和神经纤维瘤样特征的标本,通过形态学、免疫组织化学检测(CD34、S100、神经丝三联蛋白(免疫染色)(NFTP)、上皮膜抗原(EMA))进行进一步特征分析,并确认为混合性肿瘤。在43例接受神经鞘膜肿瘤切除术的NF2患者中,11例(26%)患者的11个标本被发现是良性神经鞘膜肿瘤,具有神经纤维瘤和神经鞘瘤的混合特征。免疫组织化学研究显示,神经鞘瘤成分S100阳性、CD34阴性,而神经纤维瘤成分CD34阳性、S100阳性情况不一。我们的经验强调了在NF2患者神经鞘膜肿瘤的鉴别诊断中纳入这种独特的肿瘤亚型——神经鞘瘤/神经纤维瘤混合性肿瘤的重要性,并表明神经纤维瘤和神经鞘瘤之间的关系比之前怀疑的更为密切。